Agenus is a leading immunology company. Our objective is to combat serious illnesses: cancer, infections, autoimmune disorders and neurological diseases. Using proprietary technologies, our cutting-edge products are designed to improve upon conventional therapies by permitting a better quality of life and reducing side effects. Our lead products include, Oncophage, QS-21, ATRA-IV and Aroplatin.
In the seven years since its inception, Agenus has achieved important milestones:
-Five products in clinical trials, including pivotal trials
-Five technology platforms
-More than 80 issued patents